Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART33 and CD33KO-HSPC in Refractory or Relapsed AML
NCT05945849Phase 1Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Feb 2024
- Primary completion
- Feb 2029
- Modality
- Gene Silencing, CRISPR-Cas9, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CART33 and tremtelectogene empogeditemcel in acute myeloid leukemia (AML), sponsored by University of Pennsylvania. Primary endpoints: Manufacturing feasibility at 1 month, Occurrence of dose-limiting toxicities related to CD33KO-HSPC at 3 months and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
CART33tremtelectogene empogeditemcel
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05945849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05945849.